(S)-n-叔丁基-3-(4-(2-甲氧基苯基)-哌嗪-1-基)-2-苯丙酰胺双盐酸盐 | 133025-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (S)-n-叔丁基-3-(4-(2-甲氧基苯基)-哌嗪-1-基)-2-苯丙酰胺双盐酸盐
• 中文别名: N-(1,1-二甲基乙基)-4-(2-甲氧基苯基)-ALPHA-苯基-1-哌嗪丙酰胺
• 英文名称: N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide
• 英文别名: WAY-100135；N-(1,1-dimethylethyl)-4-(2-methoxyphenyl)-α-phenyl-1-piperazinepropanamide；N-tert-butyl-3-(4-(2-methoxyphenyl)piperazine-1-yl)-2-phenylpropanamide；N-tert-butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide；tert.-butyl-3,4-(2-methoxyphenyl)piperazin-1-yl-2-phenyl-propanamide；WAY 100135；N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide
• CAS: 133025-23-7
• 化学式: C₂₄H₃₃N₃O₂
• 分子量: 395.545
• InChiKey: UMTDAKAAYOXIKU-UHFFFAOYSA-N

物化性质

• 熔点：
  >183°C (dec.)
• 沸点：
  582.8±50.0 °C(Predicted)
• 密度：
  1.085
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-苯基丙烯酸 在 N,N'-羰基二咪唑 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 生成 (S)-n-叔丁基-3-(4-(2-甲氧基苯基)-哌嗪-1-基)-2-苯丙酰胺双盐酸盐
  参考文献：
  名称：

  （S）-N-叔丁基-3-（4-（2-甲氧基苯基）-哌嗪-1-基）-2-苯基丙酰胺[（S）-WAY-100135]：突触前和突触后5-的选择性拮抗剂HT1A受体。

  摘要：

  DOI：

  10.1021/jm00062a028

文献信息

• Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds
  申请人：——

  公开号：US20020010198A1

  公开（公告）日：2002-01-24

  Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

  本发明揭示了治疗和预防多种疾病和症状的方法，包括但不限于：进食障碍；体重增加；肥胖症；肠易激综合征；强迫症；血小板粘附；呼吸暂停；情感障碍，如注意力缺陷障碍、抑郁症和焦虑症；男性和女性性功能障碍；不宁腿综合征；骨关节炎；物质滥用，包括尼古丁和可卡因成瘾；嗜睡症；疼痛，如神经病性疼痛、糖尿病神经病变和慢性疼痛；偏头痛；脑功能障碍；经前综合症和失禁。此外，还揭示了包含外消旋或光学纯度西布曲明代谢物和可选的其他药理活性化合物的制药组合物和剂型。
• [EN] METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS<br/>[FR] PROCEDES D'UTILISATION D'INHIBITEURS DE RECAPTAGE DE LA DOPAMINE ET COMPOSITIONS CONTENANT CES DERNIERS
  申请人：SEPRACOR INC

  公开号：WO2000010551A2

  公开（公告）日：2000-03-02

  Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites like desmethylsibutramine and didesmethylsibutramine and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3, antagonists.

  本发明涉及治疗和预防多种疾病和症状的方法，包括但不限于勃起功能障碍、情感障碍、体重增加、脑功能障碍、疼痛、强迫症、物质滥用、慢性疾病、焦虑、进食障碍、偏头痛和失禁。该方法包括给予多巴胺再摄取抑制剂和可选的其他药理活性化合物。还公开了包含多巴胺再摄取抑制剂和可选的其他药理活性化合物的制药组合物和剂型。优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物，如去甲基西布曲明和二去甲基西布曲明及其药学上可接受的盐、溶剂和包合物。优选的其他药理活性化合物包括影响中枢神经系统的药物，如5-HT3拮抗剂。
• Compositions comprising dopamine reuptake inhibitors and methods of making and using the same
  申请人：Sepracor Inc.

  公开号：US20020183281A1

  公开（公告）日：2002-12-05

  Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.

  本发明揭示了制备和使用西布曲明的外消旋体和光学纯异构体代谢物以及其药学上可接受的盐、溶剂合物和包合物的方法。同时还揭示了制备药物组合物和剂型的方法，其中包括多巴胺再摄取抑制剂，例如外消旋体或光学纯的西布曲明代谢物，以及可选的另一种药理活性化合物。
• Methods of treating or preventing restless leg syndrome using sibutramine metabolites
  申请人：——

  公开号：US20040067957A1

  公开（公告）日：2004-04-08

  Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

  本发明公开了一种治疗和预防多种疾病和症状的方法，包括但不限于：进食障碍、体重增加、肥胖、肠易激综合征、强迫症、血小板粘附、呼吸暂停、注意力缺陷障碍、抑郁症和焦虑症、男女性功能障碍、不宁腿综合征、骨关节炎、物质滥用，包括尼古丁和可卡因成瘾、嗜睡症、神经性疼痛、糖尿病性神经病和慢性疼痛、偏头痛、脑功能障碍、经前综合症和失禁。本发明还公开了含有外消旋或光学纯度西布曲明代谢物和可选的其他药理活性化合物的制药组合物和剂型。
• Methods of treating or preventing weight gain, obesity, and related disorders
  申请人：Sepracor Inc.

  公开号：US20020188029A1

  公开（公告）日：2002-12-12

  Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT 3 antagonists.

  本发明揭示了用于治疗和预防多种疾病和症状的方法，包括但不限于勃起功能障碍、情感障碍、体重增加、脑功能障碍、疼痛、强迫症障碍、物质滥用、慢性疾病、焦虑、进食障碍、偏头痛和失禁。该方法包括给予多巴胺再摄取抑制剂和可选的其他药理活性化合物。本发明还揭示了包含多巴胺再摄取抑制剂和可选的其他药理活性化合物的制药组合物和剂型。优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物及其药学上可接受的盐、溶剂和包合物。优选的其他药理活性化合物包括影响中枢神经系统的药物，如5-HT3拮抗剂。